| Income Statement | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Cost of sales | 11,922 | 26,841 | ||
| Gross profit | -11,922 | -26,841 | ||
| Depreciation | 64,689 | 63,807 | ||
| Impairment charge | - | 1,674,000 | ||
| Professional fees | 140,865 | 158,077 | ||
| Research and development | 77,494 | 340,907 | ||
| Salaries and wages | 356,650 | 432,308 | ||
| Selling, general and administrative | 212,753 | 247,464 | ||
| Operating expenses | 852,451 | 2,916,563 | ||
| Operating income (loss) | -864,373 | -2,943,404 | ||
| Gain on sale of r&d assets | 50,097 | - | ||
| Loss on disposal of property & equipment | -172,684 | - | ||
| Dividend income | 31,852 | 112,663 | ||
| Interest income | 62,830 | - | ||
| Interest expense, nonoperating | 3,424 | 813 | ||
| Nonoperating income (expense) | -31,329 | 111,850 | ||
| Income (loss) from continuing operations before interest expense, interest income, income taxes, noncontrolling interests, net | -895,702 | -2,831,554 | ||
| Net loss | -895,702 | -2,831,554 | ||
| Basic eps | -0.06 | -0.18 | ||
| Diluted eps | -0.06 | -0.18 | ||
| Basic average shares | 15,754,774 | 15,754,774 | ||
| Diluted average shares | 15,754,774 | 15,754,774 | ||
null (FRZA)
null (FRZA)